Skip to main content

Table 1 General characteristics and laboratory markers of assessed patients with rheumatoid arthritis and control subjects

From: Assessment of intracranial vessels in association with carotid atherosclerosis and brain vascular lesions in rheumatoid arthritis

 

RA total

RA MTX

RA biologic

Control subjects

No. of subjects

41

12

29

60

Age, years

58.24 ± 9.72

58.67 ± 9.88

58.07 ± 9.88

58.42 ± 4.41

Disease duration. years

12.15 ± 8.03

11.00 ± 8.63

12.62 ± 7.87

RF positivity, %

70%

82%

66%

Anti-CCP positivity, %

65%

75%

64%

MTX duration, years

6.15 ± 5.82

5.83 ± 4.57

6.28 ± 3.54

MTX dose, mg/week

14.63 ± 6.11

14.17 ± 5.15

14.83 ± 6.54

Biologic duration, years

5.31 ± 2.04

5.31 ± 2.04

DAS28

2.44 ± 0.87

2.88 ± 0.75

2.26 ± 0.86

ESR, mm/h

17.07 ± 15.09

17.00 ± 9.16

17.10 ± 17.10

5.30 ± 2.40

hsCRP, mg/L

3.93 ± 4.53

5.31 ± 3.90

3.36 ± 4.70

0.30 ± 0.30

BMI, kg/m2

28.38 ± 5.51

28.08 ± 6.77

28.51 ± 5.02

30.20 ± 8.70

TC, mmol/L

5.34 ± 1.08

5.63 ± 1.00

5.23 ± 1.10

5.27 ± 1.15

HDL-C, mmol/L

1.47 ± 0.43

1.38 ± 0.53

1.49 ± 0.40

1.70 ± 0.42

TC/HDL-C ratio

3.94 ± 1.36

4.70 ± 3.73

3.73 ± 1.20

3.62 ± 0.95

LDL-C, mmol/L

3.17 ± 0.82

3.36 ± 0.90

3.12 ± 0.81

3.40 ± 0.94

TG, mmol/L

1.46 ± 0.68

1.53 ± 0.76

1.43 ± 0.66

1.49 ± 0.61

Lp(a), ng/L

260.14 ± 317.20

345.29 ± 426.55

239.59 ± 290.74

ApoA/ApoB ratio

1.81 ± 0.51

1.71 ± 0.49

1.83 ± 0.53

  1. Abbreviations: Apo Apolipoprotein, BMI Body mass index, CCP Cyclic citrullinated peptide, CRC Cerebrovascular reserve capacity, DAS28 28-joint Disease Activity Score, ESR Erythrocyte sedimentation rate, HDL-C High-density lipoprotein cholesterol, hsCRP High-sensitivity C-reactive protein, LDL-C Low-density lipoprotein cholesterol, Lp(a) Serum lipoprotein A, MTX Methotrexate, RA Rheumatoid arthritis, RF Rheumatoid factor, TC Total cholesterol, TG Triglyceride